

Electronic Supplementary Information (ESI)

A cavity-shaped *cis*-chelating P,N ligand for highly selective nickel-catalysed ethylene dimerisation

Yang Li,^a Katrin Pelzer,^a Damien Sechet,^b Geordie Creste,^a Dominique Matt,^b Pierre Braunstein,^{*a}
Dominique Armspach^{*a}

^a Equipe Confinement Moléculaire et Catalyse, Institut de Chimie de Strasbourg,
UMR 7177 CNRS, Université de Strasbourg, 4, rue Blaise Pascal, CS 90032, 67081
Strasbourg Cedex, France,

^b Laboratoire de Chimie Inorganique Moléculaire et Catalyse, Institut de Chimie de
Strasbourg, UMR 7177 CNRS, Université de Strasbourg, 4, rue Blaise Pascal, CS
90032, 67081 Strasbourg cedex, France,


Content

Experimental Details.....	2
1. General methods.....	2
2. Synthesis and characterisation of compounds 3, 4, 1, 7, 9, 10, 8, 11, 12, 13	3
3. Procedure for ethylene oligomerisation reactions.....	12
4. NMR and mass spectra of 3, 4, 1, 7, 9, 10, 8, 11, 12, 13	13
5. Crystal structure analyses.....	57
6. UV-visible Spectra.....	71
References.....	72

Experimental Details


1. General methods

All reactions and manipulations were carried out under an inert atmosphere (nitrogen or argon) using standard Schlenk techniques. All glassware was stored in the oven prior to use under an inert atmosphere of gas (Argon). All commercial reagents were used as supplied unless otherwise stated. Solvents were dried by conventional methods and distilled immediately prior to use. Deuterated solvents were passed through a 5 cm-thick alumina column and stored under nitrogen over molecular sieves (4 Å). Column chromatography was performed on silica gel 60 (particle size 40-63 µm, 230-240 mesh). Routine ^1H , $^{31}\text{P}\{^1\text{H}\}$ and $^{13}\text{C}\{^1\text{H}\}$ NMR spectra were recorded on Bruker FT instruments (AVANCE 300, 400, 500, 600 spectrometers) at room temperature unless otherwise stated. ^1H NMR spectral data were referenced to residual protiated solvents ($\delta = 7.26$ ppm for CDCl_3 , 7.15 ppm for C_6D_6 and 5.32 ppm for CD_2Cl_2), $^{13}\text{C}\{^1\text{H}\}$ chemical shifts are reported relative to deuterated solvents ($\delta = 77.16$ ppm for CDCl_3 , 128.02 ppm for C_6D_6 and 53.84 ppm for CD_2Cl_2) and the $^{31}\text{P}\{^1\text{H}\}$ NMR data are given relative to external H_3PO_4 . Mass spectra were recorded on a Bruker MicroTOF spectrometer (ESI-TOF) using CH_2Cl_2 , CH_3CN or CH_3OH as the solvent. Elemental analyses were performed by the Service de Microanalyse, Institut de Chimie UMR 7177, Strasbourg. Melting points were determined with a Buchi 535 capillary melting point apparatus. Dimesylate **5**¹, diethyl 2-amino-1-phenylphosphonate,² *N,N*-dimethyl-2-diethylphosphinoaniline³⁻⁵ via 2-bromo-*N,N*-dimethylaniline⁶ were prepared according to literature procedures. In this publication, the cyclodextrins are depicted as seen from the secondary face, the glucose units being ranged counterclockwise in the following order: A, B, C, D, E, F. The numbering of the atoms within a glucose unit is as follows:




2. Synthesis and characterisation

Diethyl [2-(*N,N*-dimethylamino)phenyl]phosphonate (**3**)⁷



Diethyl 2-amino-1-phenylphosphonate² (530 mg, 2.31 mmol), anhydrous K₂CO₃ (1.60 g, 11.56 mmol), methyl iodide (0.72 mL, 11.56 mmol) and dry DMF (5 mL) were placed in a 25 mL flask equipped with a condenser and stirred at 70 °C overnight. The reaction was cooled to room temperature before adding distilled H₂O (15 mL). The mixture was extracted with Et₂O (20 mL). The resulting aqueous layer was then further extracted with Et₂O (3 x 20 mL). The combined organic layers were washed with brine (3 x 15 mL), dried over MgSO₄ before being evaporated to dryness. The crude was then subjected to column chromatography (SiO₂; AcOEt/PE, 80/20, v/v) to afford **3** (510 mg, 86%) as yellow oil. *R*_f (SiO₂, AcOEt/PE, 90/10, v/v) = 0.26; ¹H NMR (400 MHz, CDCl₃, 25 °C): δ = 1.35 (t, ³*J* = 7.1 Hz, 6H, OCH₂CH₃), 2.79 (s, 6H, NMe₂), 4.16 (m, 4H, OCH₂CH₃), 7.12 (m, 1H, aromatic H), 7.25 (m, 1H, aromatic H), 7.47 (m, 1H, aromatic H), 7.81 (m, 1H, aromatic H); ³¹P{¹H} NMR (121 MHz, CDCl₃, 25 °C): δ = 18 ppm. All spectral data are consistent with the literature values.⁷


2-(*N,N*-Dimethylamino)phenylphosphine (**4**)⁸



Pure Me₃SiCl (2.36 mL, 18.6 mmol) was added to a suspension of LiAlH₄ (71 mg, 18.6 mmol) in THF (20 mL) at -78 °C. The reaction mixture was allowed to reach room temperature and stirred for 2 h. A solution of phosphonate **3** (1.60 g, 6.2 mmol) in THF (6 mL) was then cannulated to the mixture at -30 °C and stirred for 1.5 h at 0 °C. The solvent was removed *in vacuo* and the residue was extracted with NaOH/Et₂O under argon to avoid phosphine oxidation. The organic layer was dried over MgSO₄. The solvent was finally removed under vacuum to afford primary phosphine **4** (0.56 g, 58%) as a colourless oil. The crude was used for the synthesis of **1** without further purification. *R*_f (SiO₂, AcOEt/PE, 70/30, v/v) = 0.95; ¹H NMR (400 MHz, CDCl₃, 25 °C): δ = 2.73 (s, 6H, NMe₂), 3.91 (d,

2H, $^1J_{\text{PH}} = 204$ Hz, PH_2), 6.98 (m, 1H, aromatic H), 7.12 (m, 1H, aromatic H), 7.27 (m, 1H, aromatic H), 7.48 (m, 1H, aromatic H); $^{31}\text{P}\{^1\text{H}\}$ NMR (161 MHz, CDCl_3 , 25 °C): $\delta = -128$ ppm. HRMS (ESI-TOF) for $\text{C}_8\text{H}_{12}\text{NP}$: m/z (%): 154.0782 (100) $[\text{M} + \text{H}]^+$. All spectral data are consistent with the literature values.⁸


6^A,6^B-Dideoxy-6^A,6^B[(*R*)-2-(*N,N*-dimethylamino)phenylphosphinidene]-2^A,2^B,2^C,2^D,2^E,2^F,3^A,3^B,3^C,3^D,3^E,3^F,6^C,6^D,6^E,6^F-hexadeca-O-methyl- α -cyclodextrin (1**)**



A solution of *n*-BuLi in hexane (1.6 M, 0.28 mL, 0.44 mmol) was added dropwise to a stirred solution of fully dried phosphine **4** (34 mg, 0.22 mmol) in 4 mL of THF at -78 °C. The mixture was then allowed to reach room temperature over a period of 1 h. The solution was cooled again to -78 °C and then added dropwise to a solution of fully dried dimesylate **5** (200 mg, 0.15 mmol) in THF (10 mL) via a cannula. The orange solution was stirred for 12 h at room temperature. The solvent was removed *in vacuo* and excess phosphide was protonated with MeOH (2 mL). The suspension was then evaporated to dryness to afford a colourless solid, which was subjected to chromatography over a short plug of silica (SiO_2 ; $\text{CH}_2\text{Cl}_2/\text{MeOH}$, 9/1, v/v). Finally, the filtrate was evaporated to dryness *in vacuo* and the resulting residue was subjected again to column chromatography (SiO_2 ; $\text{CH}_2\text{Cl}_2/\text{MeOH}$, 97:3, v/v) to afford pure **1** (122 mg, 63%) as a colourless solid. M.p. = 101-103 °C. ^1H NMR (400 MHz, CDCl_3 , 25 °C): δ (assignment by COSY and HSQC) = 1.73 (m, 1H, H-6a^B), 1.75 (m, 1H, H-6a^A), 2.68 (m, 1H, H-6b^B), 2.80 (s, 6H, NMe₂), 3.14 (m, 1H, H-6b^A), 3.23 (s, 3H, OMe), 3.24 (s, 3H, OMe), 3.38 (s, 6H, OMe), 3.46 (s, 3H, OMe), 3.47 (s, 3H, OMe), 3.48 (s, 3H, OMe), 3.49 (s, 6H, OMe), 3.50 (s, 3H, OMe), 3.60 (s, 3H, OMe), 3.63 (s, 6H, OMe), 3.64 (s, 3H, OMe), 3.65 (s, 3H, OMe), 3.67 (s, 3H, OMe), 3.11–3.90 (29H, H-2, H-3, H-4, H-5, H-6), 4.01 (m, 1H, H-5^B), 4.09 (dd, 1H, $^2J_{\text{H-6a}, \text{H-6b}} = 2.0$ Hz, $^2J_{\text{H-6}, \text{H-5}} = 10.6$ Hz, H-6), 4.30 (m, 1H, H-5^A), 4.96 (d, 1H, $^3J_{\text{H-1-H-2}} = 2.8$ Hz, H-1), 4.99 (d, 1H, $^3J_{\text{H-1-H-2}} = 2.9$ Hz, H-1), 5.02 (d, 1H, $^3J_{\text{H-1-H-2}} = 4.0$ Hz, H-1), 5.05 (d, 1H, $^3J_{\text{H-1-H-2}} = 4.2$ Hz, H-1), 5.06-5.07 (2H, H-1), 7.01-7.44 (4H,

aromatic H); ^{13}C NMR (100.6 MHz, CDCl_3 , 25 °C): δ (assignment by HSQC) = 27.38 (C-6^A or B), 34.08 (C-6^A or B), 46.10, 46.16 (-N(CH₃)₂), 57.58, 57.96 [x5], 58.95, 59.04, 59.07, 59.15, 61.77 [x3], 61.87, 62.05, 62.18 (OMe), 70.27, 71.02 (C-6), 71.05 (C-5), 71.28 (C-6), 71.32, 71.40, 71.46 (C-5), 71.56 (C-6), 72.90, 73.20 (C-5), 81.28 [x4], 81.43, 81.56 [x2], 81.66, 81.83 [x2], 82.14, 82.37 [x2], 82.52, 82.71, 83.47, 87.87, 89.18 (C-2, C-3, C-4), 97.51, 99.35, 100.01, 100.19, 100.28, 100.63 (C-1), 118.69, 123.65, 129.85, 133.48 (aromatic C), 135.12 (d, $^1J_{\text{P,C}}$ = 19.1 Hz, aromatic C), 157.27 (d, $^2J_{\text{P,C}}$ = 12.2 Hz, aromatic C); $^{31}\text{P}\{^1\text{H}\}$ NMR (121 MHz, CDCl_3 , 25 °C): δ = -28.4 ppm; elemental analysis (%) calcd for $\text{C}_{60}\text{H}_{100}\text{NO}_{28}\text{P}\cdot\text{H}_2\text{O}$: C 54.09, H 7.72, N 1.05, found: C 54.13, H 7.64, N 0.97; MS (ESI-TOF) for $\text{C}_{60}\text{H}_{100}\text{NO}_{28}\text{P}$: m/z (%): 1314.63 (100) [$M + \text{H}$]⁺.


***N,N*-dimethyl-2-diethylphosphinoaniline (7)**⁵



A Schlenk tube filled with argon was charged with (2-bromo-*N,N*-dimethylaniline) (320 mg, 1.60 mmol) in THF (3 mL). The solution was cooled at -78 °C and *n*-BuLi (1.92 mmol, 1.2 eq.) was added dropwise. The mixture was allowed to rise slowly to room temperature. Et₂PCl (200 mg, 1.60 mmol) was then added to the mixture at 0 °C which was stirred overnight at room temperature. The solvent was removed *in vacuo*. The residue was suspended in DCM and filtered through Celite. Removal of the solvent under reduced pressure afforded the crude filtrate which was purified by column chromatography (SiO₂; PE/DCM, 50/50, v/v) to afford **10** as a pale yellow oil (135 mg, 40%). ^1H NMR (500 MHz, CDCl_3 , 25 °C) : δ = 0.98 (t, 3J = 7.5 Hz, 3H, PCH_2CH_3), 1.03 (t, 3J = 7.5 Hz, 3H, PCH_2CH_3), 1.69 (m, 4H, PCH_2CH_3), 2.75 (m, 6H, NMe_2), 7.09 (m, 1H, aromatic H), 7.14 (m, 1H, aromatic H), 7.25-7.34 (2H, aromatic H), $^{31}\text{P}\{^1\text{H}\}$ NMR (121 MHz, CDCl_3 , 25 °C): δ = -25.05 ppm. HRMS (ESI-TOF) for $\text{C}_{12}\text{H}_{20}\text{NP}$: m/z (%): 210.1406 (100) [$M + \text{H}$]⁺. All spectral data are consistent with the literature values.⁵

Dibromo-[{6^A,6^B-Dideoxy-6^A,6^B-[(*R*)-2-(*N,N*-dimethylamino)phenylphosphinidene]-2^A,2^B,2^C,2^D,2^E,2^F,3^A,3^B,3^C,3^D,3^E,3^F,6^C,6^D,6^E,6^F-hexadeca-O-methyl

- α -cyclodextrin}- κ^2 P,N]nickel(II) (9**)**




To a solution of **1** (271.5 mg, 0.21 mmol) in CH_2Cl_2 (10 mL) was added dropwise a solution of $[\text{NiBr}_2(\text{DME})]$ (73 mg, 0.21 mmol) in CH_2Cl_2 . The reaction mixture was stirred for 2 h at room temperature. The solution was evaporated to dryness under reduced pressure. The resulting violet residue was redissolved with benzene and

then filtered through a pad of Celite. The filtrate was evaporated *in vacuo* to afford **9** as a violet solid (205 mg, 64.7%). A crystalline material was obtained by slow diffusion of *n*-pentane into a benzene solution of **9**. ^1H NMR (500 MHz, CD_2Cl_2 , 25 °C): δ (assignment by COSY and HSQC) = 2.96-4.13 (27H, H-2, H-3, H-4, H-5^{C,D,E,F}, H-6), 3.38 (s, 3H, OMe), 3.39 (s, 3H, OMe), 3.44 (s, 3H, OMe), 3.45 (s, 6H, OMe), 3.45 (s, 3H, OMe), 3.46 (s, 3H, OMe), 3.50 (s, 3H, OMe), 3.53 (s, 3H, OMe), 3.55 (s, 3H, OMe), 3.56 (s, 3H, OMe), 3.56 (s, 3H, OMe), 3.57 (s, 3H, OMe), 3.58 (s, 3H, OMe), 3.59 (s, 3H, OMe), 3.61 (s, 3H, OMe), 4.36 (m, 2H, H-5^{A or B}, H-6), 4.47 (d, 1H, $J = 10.9$ Hz, H-6), 4.95 (1H, $^3J_{\text{H1-H2}} = 3.4$ Hz, H-1), 4.98 (2H, H-1, H-5^{B or A}), 4.99-5.03 (2H, H-1), 5.02 (m, 1H, H-6), 5.09-5.12 (m, 2H, H-1), 7.29-7.66 (4H, aromatic H), signal for NMe_2 is too broad to be identified; ^{13}C NMR (126 MHz, CD_2Cl_2 , 25°C): δ (assignment by HSQC) = 57.62, 57.65, 57.78, 57.78, 57.79, 57.98, 58.97, 58.98, 59.26, 61.26, 61.53, 61.69, 61.80, 61.83, 62.12, 62.34 (OMe), 67.29, 68.85 (br, C-5^{A,B}), 70.65, 71.01, 71.11, 71.33 (C-5^{C,D,E,F}), 72.18, 72.55, 72.75, 73.39 (C-6^{C,D,E,F}), 80.79, 81.65, 81.69, 81.78, 81.88 [x2], 82.01, 82.14 [x2], 82.38, 82.53, 82.67, 82.73, 82.86, 83.02, 83.53, 88.58, 90.32 (C-2, C-3, C-4), 98.48, 99.92, 99.96, 100.31, 100.42, 101.67 (C-1), 121.75 (br), 128.69, 130.90 (br), 134.24 (aromatic C), C-6^{A,B}, NMe_2 and two quaternary aromatic carbons could not be identified because of signal broadness; $^{31}\text{P}\{^1\text{H}\}$ NMR (243 MHz, CD_2Cl_2 , -60 °C): $\delta = 10.40$ ppm; elemental analysis (%) calcd for


C₆₀H₁₀₀Br₂NO₂₈PNi•0.25 C₅H₁₂: C 47.43, H 6.69, N 0.90, found: C 47.26, H 6.88, N 0.98; MS (ESI-TOF) for C₆₀H₁₀₀Br₂NO₂₈PNi: *m/z* (%): 1452.47 (100) [*M* - Br]⁺.

Dibromo[(*N,N*-dimethyl-2-diethylphosphinoaniline)-κ²P,N]nickel(II) (10)



Solid NiBr₂ (124 mg, 0.57 mmol) was added to a solution of **7** (120 mg, 0.57 mmol) in CH₂Cl₂ (16 mL) under argon. The reaction mixture was stirred for 22 h at room temperature and filtered through a Celite pad under argon. The filtrate was concentrated to 3–4 mL *in vacuo* and 30 mL Et₂O was added to precipitate a dark red solid. The supernatant was removed with a syringe. The solid was washed with Et₂O and dried under reduced pressure to afford **10** as a dark red solid (180 mg, 74%). A crystalline material was obtained by slow diffusion of *n*-hexane into a dichloromethane solution of **10**. ¹H NMR (600 MHz, CD₂Cl₂, -60 °C): δ = 1.44–1.35 (m, 6H, PCH₂CH₃), 1.64 (dt, ³*J* = 15.3, 7.7 Hz, 2H, PCH₂CH₃), 2.35 (dt, ³*J* = 15.1, 7.8 Hz, 2H, PCH₂CH₃), 3.13 (s, 6H, NMe₂), 7.41 (m, 3H, aromatic-H), 7.55 (m, 1H, aromatic-H); ³¹P{¹H} NMR (243 MHz, CD₂Cl₂, -60 °C): δ = 41.4 ppm; elemental analysis (%) calcd for C₁₂H₂₀Br₂NNiP: C 33.69, H 4.71, N 3.27, found: C 33.02, H 4.68, N 3.21; HRMS (ESI-TOF): *m/z* (%): 347.9846 (100) [*M* - Br]⁺.


Dichloro[{6^A,6^B-Dideoxy-6^A,6^B-[(*R*)-2-(*N,N*-dimethylaminophenyl)phosphinidene]-2^A,2^B,2^C,2^D,2^E,2^F,3^A,3^B,3^C,3^D,3^E,3^F,6^C,6^D,6^E,6^F-hexadeca-O-methyl-α-cyclodextrin}]-κ²P,N]palladium(II) (8)



A solution of [PdCl₂(COD)] (108 mg, 0.38 mmol) in CH₂Cl₂ (4 mL) was added dropwise to a solution of **1** (500 mg, 0.38 mmol) in CH₂Cl₂ (4 mL). The reaction mixture was stirred for 2 h at room temperature and then evaporated to dryness under reduced pressure. The resulting yellow residue was subjected to column chromatography (SiO₂, CH₂Cl₂/MeOH, 97/3, *v/v*) to

afford pure **8** (465 mg, 82%) as a yellow solid. A crystalline material was obtained by slow diffusion of *n*-pentane into a butanone solution of **8**. ¹H NMR (500 MHz, CDCl₃, 25 °C): δ (assignment by COSY and HSQC) = 2.14 (m, 2H, H-6^A or ^B), 3.06 (dd, 1H, ³J_{H2-H3} = 10.1 Hz, ³J_{H2-H1} = 2.9 Hz, H-2), 3.11–3.19 (4H, H-2), 3.21 (1H, H-6^A or ^B), 3.26 (dd, 1H, ³J_{H2-H3} = 9.3 Hz, ³J_{H2-H1} = 4.2 Hz, H-2), 3.37 (s, 3H, OMe), 3.41 (s, 3H, OMe), 3.43 (s, 6H, NMe₂), 3.44 (s, 6H, OMe), 3.44 (s, 3H, OMe), 3.45 (s, 3H, OMe), 3.46 (s, 6H, OMe), 3.50 (s, 3H, OMe), 3.55 (s, 3H, OMe), 3.58 (s, 3H, OMe), 3.60 (s, 3H, OMe), 3.61 (s, 3H, OMe), 3.63 (s, 3H, OMe), 3.65 (s, 3H, OMe), 3.67 (s, 3H, OMe), 3.35–3.85 (15H, H-3, H-4, H-6), 3.87–3.95 (3H, H-5, H-6), 3.98 (d, 1H, *J* = 11.4 Hz, H-6), 4.15 (d, 1H, *J* = 11.1 Hz, H-6), 4.18–4.28 (4H, H-5, H-6), 4.56 (m, 1H H-5^A or ^B, H-6), 4.59 (m, 1H, H-5^A or ^B), 4.93 (d, 1H, *J* = 3.1 Hz, H-1), 5.03 (d, 1H, *J* = 2.6 Hz, H-1), 5.06 (2H, H-1), 5.08 (2H, H-1), 5.19 (m, 1H, H-5^A or ^B), 7.51–7.68 (4H, aromatic H) ppm; ¹³C NMR (100.6 MHz, CDCl₃, 25 °C): δ (assignment by HSQC) = 31.62 (d, ¹J_{C6-P} = 32.6 Hz, C-6^A or ^B), 41.15 (d, ¹J_{C6-P} = 28.0 Hz, C-6^A or ^B), 55.21, 55.48, 57.42, 57.53, 57.68 (OMe), 57.79, 57.82 (NMe₂), 57.90, 59.13 [x2], 59.31, 59.43, 61.78, 61.84, 61.95 [x2], 62.27, 62.55 (OMe), 65.69 (d, ²J_{C5-P} = 6.1 Hz, C-5^A or ^B), 67.35 (C-5^A or ^B), 70.02, 70.64, 70.82, 71.01 (C-5), 71.46, 72.03, 72.28, 72.97 (C-6), 80.03, 81.09, 81.13, 81.29, 81.44, 81.52, 81.67, 81.98, 82.07 [x2], 82.28 [x3], 82.55, 82.59, 82.62, 87.96, 90.07 (C-2, C-3, C-4), 98.14, 99.68, 99.99, 100.11, 100.65, 101.32 (C-1), 122.00 (d, ²J_{P,C} = 11.7 Hz, aromatic C), 130.89 (d, ³J_{P,C} = 6.6 Hz, aromatic C), 131.52 (aromatic C), 131.60 (d, ¹J_{P,C} = 47.1 Hz, aromatic C), 134.60 (aromatic C), 159.32 (d, ²J_{P,C} = 16.2 Hz, aromatic C); ³¹P{¹H} NMR (121 MHz, CDCl₃, 25 °C): δ = 32.5 ppm; elemental analysis (%) calcd for C₆₀H₁₀₀Cl₂NO₂₈PPd•0.15 CH₂Cl₂: C 48.02, H 6.72, N 0.93, found: C 47.71, H 6.82, N 0.94; MS (ESI-TOF) for C₆₀H₁₀₀Cl₂NO₂₈PPd: *m/z* (%): 1456.49 (100) [*M* – Cl]⁺.


Dichloro[(*N,N*-dimethyl-2-diethylphosphinoaniline)-κ²P,N]palladium(II) (**11**)



A solution of $[\text{PdCl}_2(\text{PhCN})_2]$ (126 mg, 0.31 mmol) was added to a solution of **7** (66 mg, 0.31 mmol) in CH_2Cl_2 (8 mL). The mixture was stirred at room temperature for 20 h and then filtered through Celite.

The filtrate was concentrated under reduced pressure and after removal of the solvent under reduced pressure, a yellow solid was obtained which was subjected to column chromatography (SiO_2 ; $\text{CH}_2\text{Cl}_2/\text{MeOH}$, 98:2→90:10, v/v) to afford two fractions. The first one contained **11** (69 mg, 58%) and the second one **12** (7 mg, 11%). Recrystallisation of **11** was performed by slow diffusion of *n*-pentane into a dichloromethane solution of **11** to afford a yellow crystalline solid (59 mg, 48%). ^1H NMR (500 MHz, CD_2Cl_2 , 25 °C): δ = 1.17 (t, $^3J = 7.5$ Hz, 3H, PCH_2CH_3), 1.22 (t, $^3J = 7.5$ Hz, 3H, PCH_2CH_3), 1.87 (m, 2H, PCH_2CH_3), 2.46 (m, 2H, PCH_2CH_3), 3.42 (s, 6H, NMe_2), 7.58-7.46 (2H, aromatic H), 7.63 (m, 1H, aromatic H), 7.70 (m, 1H, aromatic H). ^{13}C NMR (126 MHz, CD_2Cl_2 , 25 °C, assignments from HMQC and HMBC): 8.84 (d, $^2J_{\text{P,C}} = 1.3$ Hz, PCH_2CH_3), 20.78 (d, $^1J_{\text{P,C}} = 36.5$ Hz, PCH_2CH_3), 55.50 (d, $^3J_{\text{P,C}} = 1.0$ Hz, NMe_2), 122.57 (d, $^2J_{\text{P,C}} = 11.7$ Hz, aromatic C), 126.48 (d, $^1J_{\text{P,C}} = 41.3$ Hz, aromatic C), 130.68 (d, $^3J_{\text{P,C}} = 6.5$ Hz, aromatic C), 130.80 (aromatic C), 134.94 (d, $^3J_{\text{P,C}} = 2.3$ Hz, aromatic C), 162.41 (d, $^2J_{\text{P,C}} = 14.7$ Hz, aromatic C); $^{31}\text{P}\{^1\text{H}\}$ NMR (121 MHz, CD_2Cl_2 , 25 °C): δ = 62.1 ppm. elemental analysis (%) calcd for $\text{C}_{12}\text{H}_{20}\text{NPPdCl}_2$: C 37.28, H 5.21, N 3.62, found: C 37.26, H 5.24, N 3.46; HRMS (ESI-TOF) for $\text{C}_{12}\text{H}_{20}\text{Cl}_2\text{NPPd}$: m/z (%): 350.0038 $[\text{M} - \text{Cl}]^+$.

[Chloro[*N,N*-dimethyl-2-diethylphosphinoaniline)- κ^2 -P,N][*N,N*-dimethyl-2-diethylphosphinoaniline)- κ' -P]palladium(II) chloride (12**)**



The above procedure was used to prepare the cationic palladium complex **12** from $[\text{PdCl}_2(\text{PhCN})_2]$ (73 mg, 0.18 mmol) and **7** (76 mg, 0.36 mmol, 2 equiv.) in CH_2Cl_2 (12 mL). Again two fractions were collected. The first one contained **11** (20 mg, 28 %) and the second one **12** (77 mg, 72%). Yellow single crystals of **12** were

obtained by slow diffusion of *n*-pentane into a dichloromethane solution. ^1H NMR (500

MHz, CDCl₃, 25°C) : δ = 0.95 (br t, 3H, 3J = 7.5 Hz, PCH₂CH₃), 0.99 (br t, 3H, 3J = 7.5 Hz, PCH₂CH₃), 1.15 (br t, 3H, 3J = 7.5 Hz, PCH₂CH₃), 1.19 (br t, 3H, 3J = 7.5 Hz, PCH₂CH₃), 2.32-2.57 (m, 6H, PCH₂CH₃), 2.76 (s, 6H, NMe₂), 3.09-3.41 (8H, NMe₂, PCH₂CH₃), 7.36 (m, 1H, aromatic H), 7.42-7.50 (2H, aromatic H), 7.55-7.70 (4H, aromatic H), 8.35 (m, 1H, aromatic H); ¹³C NMR (126 MHz, CD₂Cl₂, 25°C, assignments from HMQC and HMBC): 9.12, 9.41 (PCH₂CH₃), 18.79 (d, $^1J_{P,C}$ = 32.3 Hz, PCH₂CH₃), 21.68 (d, $^1J_{P,C}$ = 31.5 Hz, PCH₂CH₃), 47.12, 53.31 (NMe₂), 121.65, 124.41, 126.74, 127.61, 128.10, 131.33, 131.94, 133.15, 133.29, 134.46, 156.54, 158.96 (aromatic C). ³¹P{¹H} NMR (121 MHz, CD₂Cl₂, 25°C): δ = 56 (d, $^2J_{PP}$ = 13.1 Hz), 21.9 (d, $^2J_{PP}$ = 13.3 Hz) ppm; HRMS (ESI-TOF) for C₂₄H₄₀Cl₂N₂P₂Pd: m/z (%): 561.1334 [$M - Cl$]⁺. A VT NMR experiment in CDCl₃ shows that line broadening occurs upon increasing the temperature from 273 K to 323 K with the two phosphorus signals beginning to merge at 323 K. Possibly, this fluxional behaviour is in keeping with the slow coordination and decooordination of the weak nitrogen donor atoms at the NMR time scale (see drawing below).





Figure S1. Possible coordination and decooordination processes taking place in **12**
Chloro[{6^A,6^B-Dideoxy-6^A,6^B-[(*R*)-2-(*N,N*-dimethylaminophenyl)phosphinidene]-
2^A,2^B,2^C,2^D,2^E,2^F, 3^A,3^B,3^C,3^D,3^E,3^F, 6^C,6^D,6^E,6^F-hexadeca-O-methyl- α -
cyclodextrin}- κ P]gold(I) (13**)**



A solution of [AuCl(tht)] (42.2 mg, 0.13 mmol) in CH₂Cl₂ (4 mL) was added dropwise to a solution of **1** (173 mg, 0.13 mmol) in CH₂Cl₂ (4 mL). The reaction mixture was stirred for 3 h at room temperature. The solution was evaporated to dryness under reduced pressure and the resulting pale-yellow residue was subjected to

column chromatography (SiO₂, CH₂Cl₂/MeOH, 97/3, v/v) to afford **13** (83.7 mg, 41%) as a pale-yellow solid. A crystalline material was obtained by slow diffusion of *n*-pentane into a benzene solution of **13**. ¹H NMR (500 MHz, CDCl₃, 25 °C): δ (assignment by COSY) = 2.17-2.30 (2H, H-6^{A,B}), 2.73 (s, 6H, NMe₂), 3.25 (m, 1H, H-4^{A or B}), 3.39 (s, 6H, OMe), 3.40 (s, 3H, OMe), 3.43 (s, 3H, OMe), 3.45 (s, 3H, OMe), 3.48 (s, 3H, OMe), 3.49 (s, 6H, OMe), 3.52 (s, 3H, OMe), 3.54 (m, 1H, H-6^{A or B}), 3.57 (m, 1H, H-6^{A or B}), 3.59 (m, 1H, H-3^{A or B}), 3.61 (s, 3H, OMe), 3.64 (s, 6H, OMe), 3.66 (s, 6H, OMe), 3.66 (m, 1H, H-3^{A or B}), 3.70 (s, 3H, OMe), 3.71 (s, 3H, OMe), 3.13-3.85 (27H, H-2, H-3, H-4, H-5, H-6), 4.10 (m, 1H, H-5^{A or B}), 4.56 (m, 1H, H-5^{A or B}), 4.96 (d, 1H, ³J_{H1-H2} = 3.2 Hz, H-1), 5.02 (d, 1H, ³J_{H1-H2} = 4.3 Hz, H-1), 5.05 (d, 1H, ³J_{H1-H2} = 2.9 Hz, H-1), 5.09 (d, 1H, ³J_{H1-H2} = 3.2 Hz, H-1), 5.11 (m, 2H, H-1), 7.30-7.72 (4H, aromatic H) ppm; ¹³C NMR (126 MHz, CDCl₃, 25 °C): δ (assignment by HSQC) = 30.12 (C-6^{A or B}) ¹J_{P,C} = 34.0 Hz (d, ¹J_{P,C} = 37.8 Hz, C-6^{A or B}), 35.76 (d, ¹J_{P,C} = 34.0 Hz, C-6^{A or B}), 47.39 (-NMe₂), 57.57, 57.60, 57.78, 58.00, 58.06, 58.18, 59.22 [x2], 59.30, 59.49, 61.70, 61.83, 61.90, 62.08, 62.16, 62.77 (OMe), 64.67, 70.88 [x2], 71.15, 71.45, 71.70, 71.75, 71.87, 72.87, 73.08 (C-5, C-6^{C,D,E,F}), 80.31, 81.22, 81.26, 81.43, 81.51, 81.63, 81.65, 81.89, 81.98, 82.07, 82.22, 82.24, 82.33, 82.47, 82.81, 82.89, 87.04, 89.66 (C-2, C-3, C-4), 97.88, 99.83, 100.05, 100.16, 100.94, 101.12 (C-1), 124.99 (d, ³J_{P,C} = 6.0 Hz, aromatic C), 126.72 (d, ²J_{P,C} = 11.2 Hz, aromatic C), 128.69 (d, ¹J_{P,C} = 65.8 Hz, aromatic C), 133.52 (d, ²J_{P,C} = 11.8 Hz, aromatic C), 133.66 (d, ⁴J_{P,C} = 2.1 Hz, aromatic C), 158.56 (d, ³J_{P,C} = 5.1 Hz, aromatic C) ppm; ³¹P{¹H} NMR (121 MHz, CDCl₃, 25 °C): δ = 19.21 (s) ppm; elemental analysis (%) calcd for

C₆₀H₁₀₀NO₂₈PAuCl•0.4 CH₂Cl₂: C 45.89, H 6.43, N 0.89, found: C 45.78, H 6.53, N 0.85; MS (ESI-TOF) for C₆₀H₁₀₀NO₂₈PAuCl: *m/z* (%): 1568.54 (100) [*M* + Na]⁺.

3. Procedure for ethylene oligomerisation reactions

The catalytic reactions were performed in a magnetically stirred (1200 rpm) 145 mL stainless steel autoclave. A 125 mL glass container was used to avoid corrosion of the autoclave walls. The precatalyst solution was prepared by dissolving 1×10^{-5} mol of the complex in toluene. This solution was injected into the reactor under an ethylene flux, followed by the cocatalyst solution (400 equiv. for MMAO-12 in toluene). After injection of the catalyst and cocatalyst solutions under a constant low flow of ethylene, which is considered as the t_0 time, the reactor was immediately pressurised to 10 bar of ethylene. The 10 bar working pressure was maintained through a continuous feed of ethylene from a bottle placed on a balance to allow monitoring of the ethylene uptake. The reaction mixture was stirred for the given reaction time. At the end of each test, a dry ice bath was used to rapidly cool the reactor. When the inner temperature reached 0 °C, the ice bath was removed, allowing the temperature to slowly rise to 18 °C. The gaseous phase was then transferred into a 10 L polyethylene tank filled with water. An aliquot of this gaseous phase was transferred into a Schlenk flask, previously evacuated, for GC analysis. The amount of ethylene consumed was thus determined by differential weighting of the bottle (accuracy of the scale: 0.01g). To this amount of ethylene, the remaining ethylene (calculated using the GC analysis) in the gaseous phase was subtracted. Although this method is of limited accuracy, it was used throughout and it gave satisfactory reproducibility. The reaction mixture in the reactor was quenched *in situ* by the addition of ethanol (5 mL), transferred into a Schlenk flask, and separated from the metal complexes by trap-to-trap evaporation into a second Schlenk flask previously immersed in liquid nitrogen in order to avoid loss of product for GC analysis. Each catalytic test was performed at least twice to ensure the reproducibility of the results.

4. NMR and mass spectra

NMR spectra of all compounds were recorded in CDCl₃ at 25 °C except stated otherwise.

Diethyl (2-(*N,N*-dimethylamino)phenyl)phosphonate (3)

¹H NMR spectrum

³¹P{¹H} NMR spectrum

2-(*N,N*-Dimethylamino)phenylphosphine (4)

¹H NMR spectrum

³¹P{¹H} NMR spectrum

Full High Resolution Mass Spectrum

Partial High Resolution Mass Spectrum

6^A,6^B-Dideoxy-6^A,6^B[(*R*)-2-(*N,N*-dimethylamino)phenylphosphinidene]-2^A,2^B,2^C, 2^D,2^E,2^F,3^A,3^B,3^C,3^D,3^E,3^F,6^C,6^D,6^E,6^F-hexadeca-O-methyl- α -cyclodextrin (1)

¹H NMR spectrum

³¹P{¹H} NMR spectrum

¹³C NMR spectrum

DEPT 135 spectrum

¹H/¹³C edited HSQC spectrum

¹H/¹H COSY spectrum

¹H/¹H TOCSY spectrum

¹H/¹H ROESY spectrum

Full Mass Spectrum

Partial Mass Spectrum

2-(*N,N*-Dimethylamino)diethylphosphine (7)

¹H NMR spectrum

³¹P{¹H} NMR spectrum

¹³C{¹H} NMR spectrum

DEPT 135 spectrum

¹H/¹³C edited HSQC spectrum

¹H/¹³C HMBC spectrum

Full Mass Spectrum

Partial Mass Spectrum

Dibromo[{6^A,6^B-Dideoxy-6^A,6^B-(*R*)-2-(*N,N*-dimethylamino)phenyl

phosphinidene]-2^A,2^B,2^C,2^D,2^E,2^F,3^A,3^B,3^C,3^D,3^E,3^F,6^C,6^D,6^E,6^F,-hexadeca-O-methyl- α -cyclodextrin}- κ^2 P,N]nickel(II) (9)

¹H NMR spectrum

³¹P{¹H} NMR spectrum

¹³C NMR spectrum

DEPT 135 spectrum

¹H/¹³C edited HSQC spectrum

¹H/¹H COSY spectrum

¹H/¹H TOCSY spectrum

¹H/¹H ROESY spectrum

Full Mass Spectrum

Partial Mass Spectrum

Dibromo[(*N,N*-dimethyl-2-diethylphosphinoaniline)- κ^2 P,N]nickel(II) (10)

¹H NMR spectrum

³¹P{¹H} NMR spectrum

Full High Resolution Mass Spectrum

Partial High Resolution Mass Spectrum

Dichloro[{6^A,6^B-Dideoxy-6^A,6^B-[(*R*)-2-(*N,N*-dimethylainophenyl)phosphinidene]-2^A,2^B,2^C,2^D,2^E,2^F,3^A,3^B,3^C,3^D,3^E,3^F,6^C,6^D,6^E,6^F-hexadeca-O-methyl- α -cyclodextrin}- κ^2 P,N]palladium(II) (8)

¹H NMR spectrum

³¹P{¹H} NMR spectrum

¹³C NMR spectrum

DEPT 135 spectrum

¹H/¹³C edited HSQC spectrum

¹H/¹H COSY spectrum

¹H/¹H TOCSY spectrum

¹H/¹H ROESY spectrum

Full Mass Spectrum

Partial Mass Spectrum

Dichloro[(*N,N*-dimethyl-2-diethylphosphinoaniline)- κ^2 P,N]palladium(II) (11)

¹H NMR spectrum

³¹P{¹H} NMR spectrum

¹³C NMR spectrum

DEPT 135 spectrum

¹H/¹³C edited HSQC spectrum

¹H/¹H COSY spectrum

¹H/¹³C HMBC spectrum

Full High Resolution Mass Spectrum
Partial High Resolution Mass Spectrum

[Chloro[(*N,N*-dimethyl-2-diethylphosphinoaniline)- κ^2 -P,N][(N,N-dimethyl-2-diethylphosphinoaniline)- κ' -P]palladium(II) chloride (12)

^1H NMR spectrum
 $^{31}\text{P}\{^1\text{H}\}$ NMR spectrum
 ^{13}C NMR spectrum
DEPT 135 spectrum
 $^1\text{H}/^1\text{H}$ COSY spectrum
 $^1\text{H}/^{13}\text{C}$ edited HSQC spectrum
 $^1\text{H}/^{13}\text{C}$ HMBC spectrum
 ^1H VT NMR spectrum
 ^{31}P VT NMR spectrum
Full High Resolution Mass Spectrum
Partial High Resolution Mass Spectrum

Chloro[{6^A,6^B-Dideoxy-6^A,6^B-[(*R*)-2-(*N,N*-dimethylaminophenyl)phosphinidene]-2^A,2^B,2^C,2^D,2^E,2^F,3^A,3^B,3^C,3^D,3^E,3^F,6^C,6^D,6^E,6^F,-hexadeca-O-methyl- α -cyclodextrin}- κP]gold(I) (13)

^1H NMR spectrum
 $^{31}\text{P}\{^1\text{H}\}$ NMR spectrum
 ^{13}C NMR spectrum
DEPT 135 spectrum
 $^1\text{H}/^{13}\text{C}$ edited HSQC spectrum
 $^1\text{H}/^1\text{H}$ COSY spectrum
 $^1\text{H}/^1\text{H}$ TOCSY spectrum
 $^1\text{H}/^1\text{H}$ ROESY spectrum
Full Mass Spectrum
Partial Mass Spectrum




Figure S2. ^1H NMR spectrum of **3** in CDCl_3




Figure S3. ^{31}P NMR spectrum of **3** in CDCl_3




Figure S4. ^1H NMR spectrum of **4** in CDCl_3




Figure S5. ^{31}P NMR spectrum of **4** in CDCl_3

Service de Spectrometrie de Masse - Federation de Chimie Le Bel - FR 2010 - CNRS / UDS

Analysis Info							
Analysis Name	F10293SK.d				Acquisition Date	9/14/2021 10:08:45 AM	
Method	Tune_pos_Standard.m				Operator	BDAL@DE	
Sample Name	N-PH2				Instrument	micrOTOF II	
Acquisition Parameter							
Source Type	ESI	Capillary	4500 V	Nebulizer	0.3 Bar	Set Hexapole RF	55.0 Vpp
Ion Polarity	Positive	Dry Heater	200 °C	Dry Gas	3.0 l/min	Set Capillary Exit	100.0 V




Figure S6. Full High Resolution Mass Spectrum of 4




Figure S7. Partial High Resolution Mass Spectrum of 4




Figure S8. ^1H NMR spectrum of **1** in CDCl_3




Figure S9. ^{31}P NMR spectrum of **1** in CDCl_3




Figure S10. ^{13}C NMR spectrum of **1** in CDCl_3




Figure S11. DEPT 135 spectrum of **1** in CDCl_3




Figure S12. $^1\text{H}/^{13}\text{C}$ edited HSQC spectrum of **1** in CDCl_3




Figure S13. $^1\text{H}/^1\text{H}$ COSY spectrum of **1** in CDCl_3




Figure S14. $^1\text{H}/^1\text{H}$ TOCSY spectrum of **1** in CDCl_3




Figure S15. $^1\text{H}/^1\text{H}$ ROESY spectrum of **1** in CDCl_3


Analysis Info

Analysis Name O36496SK.d
Method esi wide pos.m
Sample Name SD71
Comment

Acquisition Date 6/10/2015 11:09:52 AM
Operator Administrator
Instrument micrOTOF

Acquisition Parameter

Source Type	ESI	Capillary	4500 V	Nebulizer	0.4 Bar	Corona	219 nA
Ion Polarity	Positive	Set Capillary Exit	150.0 V	Dry Gas	4.0 l/min	Set Hexapole RF	220.0 V
Scan Range	n/a	Set Skimmer 1	50.0 V	Dry Heater	200 °C	APCI Heater	514 °C



Bruker Daltonics DataAnalysis 3.1

printed: 6/10/2015 1:47:51 PM

Page 1 of 1

Figure S16. Full Mass Spectrum of 1


Analysis Info

Analysis Name O36496SK.d
Method esi wide pos.m
Sample Name SD71
Comment

Acquisition Date 6/10/2015 11:09:52 AM
Operator Administrator
Instrument micrOTOF

Acquisition Parameter

Source Type	ESI	Capillary	4500 V	Nebulizer	0.4 Bar	Corona	219 nA
Ion Polarity	Positive	Set Capillary Exit	150.0 V	Dry Gas	4.0 l/min	Set Hexapole RF	220.0 V
Scan Range	n/a	Set Skimmer 1	50.0 V	Dry Heater	200 °C	APCI Heater	514 °C



Bruker Daltonics DataAnalysis 3.1

printed: 6/10/2015 1:49:00 PM

Page 1 of 1

Figure S17. Partial Mass Spectrum of 1




Figure S18. ^1H NMR spectrum of **7** in CDCl_3




Figure S19. ^{31}P NMR spectrum of **7** in CDCl_3




Figure S20. ^{13}C NMR spectrum of **7** in CDCl_3




Figure S21. DEPT 135 spectrum of **7** in CDCl_3




Figure S22. $^1\text{H}/^{13}\text{C}$ edited HSQC spectrum of **7** in CDCl_3




Figure S23. $^1\text{H}/^{13}\text{C}$ HMBC spectrum of **7** in CDCl_3

Service de Spectrometrie de Masse - Federation de Chimie Le Bel - FR 2010 - CNRS / UDS

Analysis Info

Analysis Name F11097SK.d
Method Tune_pos_Standard.m
Sample Name GC-ECMC-21

Acquisition Date 01/12/2021 15:47:45
Operator BDAL@DE
Instrument micrOTOF II

Acquisition Parameter

Source Type ESI Capillary 4500 V Nebulizer 0.3 Bar Set Hexapole RF 55.0 Vpp
Ion Polarity Positive Dry Heater 200 °C Dry Gas 3.0 l/min Set Capillary Exit 100.0 V




Figure S24. Full Mass Spectrum of 7

Mass Spectrum HR Report

Analysis Info


Analysis Name V:\esi-tof2\2021\112_Decembre 2021\F11097SK.d
Method Tune_pos_Standard.m
Sample Name GC-ECMC-21
Comment

Acquisition Date 01/12/2021 15:47:45

Operator BDAL@DE
Instrument micrOTOF II 8213750.10451

Acquisition Parameter

Source Type ESI Ion Polarity Positive Set Corrector Fill 50.9 V
n/a n/a n/a n/a
Scan Begin 50 m/z n/a n/a Set Reflector 1800.0 V
Scan End 3000 m/z n/a n/a Set Flight Tube 8600.0 V
Set Detector TOF 2008.9 V



Meas. m/z	#	Ion Formula	m/z	err [ppm]	Mean err [ppm]	rdB	N-Rule	e ⁻ Conf	mSigma	Std I	Std Mean m/z	Std I	VarNorm	Std m/z Diff	Std Comb Dev
210.140100	1	C ₁₂ H ₂₁ NP	210.140613	2.4		10.4	3.5	ok	even	0.9	1.5	n.a.	n.a.	n.a.	n.a.

Figure S25. Partial Mass Spectrum of 7




Figure S26. ¹H NMR spectrum of **9** in CD₂Cl₂




Figure S27. ³¹P NMR spectrum of **9** in CD₂Cl₂ (-60°C)




Figure S28. ^{13}C NMR spectrum of **9** in CD_2Cl_2




Figure S29. DEPT 135 spectrum of **9** in CD_2Cl_2




Figure S30. $^1\text{H}/^{13}\text{C}$ edited HSQC spectrum of **9** in CD_2Cl_2




Figure S31. $^1\text{H}/^1\text{H}$ COSY spectrum of **9** in CD_2Cl_2




Figure S32. $^1\text{H}/^1\text{H}$ TOCSY spectrum of **9** in CD_2Cl_2




Figure S33. $^1\text{H}/^1\text{H}$ ROESY spectrum of **9** in CD_2Cl_2

Service de Spectrometrie de Masse - Federation de Chimie Le Bel - FR2010 - CNRS / UDS

Analysis Info

Analysis Name F09896SK.d
Method Tune_pos_Mid.m
Sample Name PN-NiBr2

Operator BDAL@DE
Instrument micrOTOF II

Acquisition Parameter

Source Type	ESI	Capillary	4500 V	Nebulizer	0.3 Bar	Set Hexapole RF	330.0 Vpp
Ion Polarity	Positive	Dry Heater	200 °C	Dry Gas	3.0 l/min	Set Capillary Exit	200.0 V




Figure S34. Full Mass Spectrum of 9

Service de Spectrometrie de Masse - Federation de Chimie Le Bel - FR2010 - CNRS / UDS

Analysis Info

Analysis Name F09896SK.d
Method Tune_pos_Mid.m
Sample Name PN-NiBr2

Operator BDAL@DE
Instrument micrOTOF II

Acquisition Parameter

Source Type	ESI	Capillary	4500 V	Nebulizer	0.3 Bar	Set Hexapole RF	330.0 Vpp
Ion Polarity	Positive	Dry Heater	200 °C	Dry Gas	3.0 l/min	Set Capillary Exit	200.0 V




Figure S35. Partial Mass Spectrum of 9




Figure S36. ^1H NMR spectrum of **10** in CD_2Cl_2 (-60°C)




Figure S37. ^{31}P NMR spectrum of **10** in CD_2Cl_2 (-60°C)

Service de Spectrométrie de Masse - Fédération de Chimie Le Bel - FR 2010 - CNRS / UDS


Analysis Info

Analysis Name F10347SK.d
Method Tune_pos_Mid.m
Sample Name GC-ECMC-23
Comment

Acquisition Date 22/09/2021 09:29:47
Operator BDAL@DE
Instrument micrOTOF II

Acquisition Parameter

Source Type	ESI	Capillary	4500 V	Nebulizer	0.3 Bar	Corona	0 nA
Ion Polarity	Positive	n/a	n/a	Dry Gas	3.0 l/min	n/a	n/a
n/a	n/a	n/a	n/a	Dry Heater	200 °C	APCI Heater	0 °C



Bruker Daltonics DataAnalysis 3.1

printed: 22/09/2021 14:23:08

Page 1 of 1

Figure S38. Full High Resolution Mass Spectra of 10

Mass Spectrum HR Report

Analysis Info


Analysis Name Y:\2021\09_Sepembre 2021\F10347SK.d
Method Tune_pos_Mid.m
Sample Name GC-ECMC-23
Comment

Acquisition Date 22/09/2021 09:29:47

Operator BDAL@DE
Instrument micrOTOF II 8213750.10451

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Corrector Fill	50.9 V
n/a	n/a	n/a	n/a	n/a	n/a
Scan Begin	50 m/z	n/a	n/a	Set Reflector	1800.0 V
Scan End	3000 m/z	n/a	n/a	Set Flight Tube	8600.0 V
				Set Detector TOF	2008.9 V



Meas. m/z	#	Ion Formula	m/z err [ppm]	Mean err [ppm]	rdB	N-Rule	e ⁻ Conf	mSigma	Std I	Std Mean m/z	Std I	VarNorm	Std m/z	Diff	Std Comb Dev
345.987040	1	C ₁₂ H ₂₀ BrNNiP	345.986466	-1.7	-1.9	3.5	ok even	7.6	7.2	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
447.895573	1	C ₁₂ H ₂₀ Br ₂ NNaNP	447.894574	-2.2	2661.1	2.5	ok even	21.6	24.0	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.

Bruker Compass DataAnalysis 4.2

printed: 22/09/2021 14:21:41

Page 1 of 1

Figure S39. Partial High Resolution Mass Spectra of 10




Figure S40. ¹H NMR spectrum of **8** in CDCl₃




Figure S41. ³¹P NMR spectrum of **8** in CDCl₃




Figure S42. ^{13}C NMR spectrum of **8** in CDCl_3




Figure S43. DEPT 135 spectrum of **8** in CDCl_3




Figure S44. $^1\text{H}/^{13}\text{C}$ edited HSQC spectrum of **8** in CDCl_3




Figure S45. $^1\text{H}/^1\text{H}$ COSY spectrum of **8** in CDCl_3




Figure S46. $^1\text{H}/^1\text{H}$ TOCSY spectrum of **8** in CDCl_3




Figure S47. $^1\text{H}/^1\text{H}$ ROESY spectrum of **8** in CDCl_3

Service de Spectrometrie de Masse - Federation de Chimie Le Bel - FR 2010 - CNRS / UDS

Analysis Info

Analysis Name F09793SK.d
Method Tune_pos_Mid.m
Sample Name YL071

Acquisition Date 6/22/2021 11:30:45 AM
Operator BDAL@DE
Instrument micrOTOF II

Acquisition Parameter

Source Type	ESI	Capillary	4500 V	Nebulizer	0.3 Bar	Set Hexapole RF	330.0 Vpp
Ion Polarity	Positive	Dry Heater	201 °C	Dry Gas	3.0 l/min	Set Capillary Exit	150.0 V




Figure S48. Full Mass Spectrum of 8

Service de Spectrometrie de Masse - Federation de Chimie Le Bel - FR 2010 - CNRS / UDS

Analysis Info

Analysis Name F09793SK.d
Method Tune_pos_Mid.m
Sample Name YI 071

Acquisition Date 6/22/2021 11:30:45 AM
Operator BDAL@DE
Instrument micrOTOF II

Acquisition Parameter

Source Type	ESI	Capillary	4500 V	Nebulizer	0.3 Bar	Set Hexapole RF	330.0 Vpp
Ion Polarity	Positive	Dry Heater	201 °C	Dry Gas	3.0 l/min	Set Capillary Exit	150.0 V




Figure S49. Partial Mass Spectrum of 8




Figure S50. ¹H NMR spectrum of **11** in CD₂Cl₂




Figure S51. ³¹P NMR spectrum of **11** in CD₂Cl₂




Figure S52. ^{13}C NMR spectrum of **11** in CD_2Cl_2




Figure S53. DEPT 135 spectrum of **11** in CD_2Cl_2




Figure S54. $^1\text{H}/^{13}\text{C}$ edited HSQC spectrum of **11** in CD_2Cl_2




Figure S55. $^1\text{H}/^1\text{H}$ COSY spectrum of **11** in CD_2Cl_2




Figure S56. $^1\text{H}/^{13}\text{C}$ HMBC spectrum of **11** in CD_2Cl_2

Service de Spectrométrie de Masse - Fédération de Chimie Le Bel - FR 2010 - CNRS / UDS


Analysis Info

Analysis Name: F10386SK.d
 Method: Tune_pos_Mid.m
 Sample Name: GC-ECMC-24-F1
 Comment:

Acquisition Date: 24/09/2021 11:24:25
 Operator: BDAL@DE
 Instrument: microTOF II

Acquisition Parameter

Source Type	ESI	Capillary	4500 V	Nebulizer	0.3 Bar	Corona	0 nA
Ion Polarity	Positive	n/a	n/a	Dry Gas	3.0 l/min	n/a	n/a
n/a	n/a	n/a	n/a	Dry Heater	200 °C	APCI Heater	0 °C



Bruker Daltonics DataAnalysis 3.1

printed: 24/09/2021 16:40:50

Page 1 of 1

Figure S57. Full High Resolution Mass Spectrum of **11**





Figure S58. Partial High Resolution Mass Spectrum of **11**






Figure S60. $^{31}\text{P}\{^1\text{H}\}$ NMR spectrum of **12** in CDCl_3




Figure S61. ^{13}C NMR spectrum of **12** in CDCl_3




Figure S62. DEPT 135 spectrum of **12** in CDCl_3




Figure S63. $^1\text{H}/^1\text{H}$ COSY spectrum of **12** in CDCl_3




Figure S64. $^1\text{H}/^{13}\text{C}$ edited HSQC spectrum of **12** in CDCl_3




Figure S65. $^1\text{H}/^{13}\text{C}$ HMBC spectrum of **12** in CDCl_3




Figure S66. ^1H VT NMR spectrum of **12** in CDCl_3




Figure S67. ^{31}P VT NMR spectrum of **12** in CDCl_3

Service de Spectrometrie de Masse - Federation de Chimie Le Bel - FR 2010 - CNRS / UDS

Analysis Info

Analysis Name F10662SK.d
Method Tune_pos_Standard.m
Sample Name GC-ECMC-25-F5 crist

Acquisition Date 10/18/2021 2:56:21 PM
Operator BDAL@DE
Instrument micrOTOF II

Acquisition Parameter

Source Type ESI Capillary 4500 V Nebulizer 0.3 Bar Set Hexapole RF 55.0 Vpp
Ion Polarity Positive Dry Heater 200 °C Dry Gas 3.0 l/min Set Capillary Exit 100.0 V




Figure S68. Full High Resolution Mass Spectrum of **12** in CDCl₃

Mass Spectrum HR Report

Analysis Info


Analysis Name D:\Data\SMasse\2021\10_Octobre 2021\F10662SK.d
Method Tune_pos_Standard.m
Sample Name GC-ECMC-25-F5 crist
Comment

Acquisition Date 10/18/2021 2:56:21 PM

Operator BDAL@DE
Instrument micrOTOF II 8213750.1045
1

Acquisition Parameter

Source Type ESI Ion Polarity Positive Set Corrector Fill 50.9 V
n/a n/a n/a n/a
Scan Begin 50 m/z Set Reflector 1800.0 V
Scan End 3000 m/z Set Flight Tube 8600.0 V
Set Detector TOF 2008.9 V



Meas. m/z # Ion Formula m/z err [ppm] Mean err [ppm] rdb N-Rule e⁻ Conf mSigma Std I Std Mean m/z Std I VarNorm Std m/z Diff Std Comb Dev
559.134248 1 C24H40ClN2P2Pd 559.138463 7.5 8.7 6.5 ok even 4.9 3.7 n.a. n.a. n.a. n.a.

Figure S69. Partial High Resolution Mass Spectrum of **12** in CDCl₃




Figure S70. ^1H NMR spectrum of **13** in CDCl_3




Figure S71. ^{31}P NMR spectrum of **13** in CDCl_3




Figure S72. ^{13}C NMR spectrum of **13** in CDCl_3




Figure S73. DEPT 135 spectrum of **13** in CDCl_3




Figure S74. $^1\text{H}/^{13}\text{C}$ edited HSQC spectrum of **13** in CDCl_3




Figure S75. $^1\text{H}/^1\text{H}$ COSY spectrum of **13** in CDCl_3




Figure S76. $^1\text{H}/^1\text{H}$ TOCSY spectrum of **13** in CDCl_3




Figure S77. $^1\text{H}/^1\text{H}$ ROESY spectrum of **13** in CDCl_3

Service de Spectrométrie de Masse - Fédération de Chimie Le Bel - FR 2010 - CNRS / UDS


Analysis Info

Analysis Name O43822SK.d
Method esi wide pos.m
Sample Name YL025
Comment

Acquisition Date 3/11/2019 2:55:46 PM
Operator admin
Instrument micrOTOF

Acquisition Parameter

Source Type	ESI	Capillary	4500 V	Nebulizer	0.3 Bar	Corona	196 nA
Ion Polarity	Positive	Set Capillary Exit	150.0 V	Dry Gas	4.0 l/min	Set Hexapole RF	300.0 V
n/a	n/a	Set Skimmer 1	50.0 V	Dry Heater	200 °C	APCI Heater	514 °C



Bruker Daltonics DataAnalysis 3.1

printed: 3/11/2019 3:03:26 PM

Page 1 of 1

Figure S78. Full Mass Spectrum of 13

Service de Spectrométrie de Masse - Fédération de Chimie Le Bel - FR 2010 - CNRS / UDS


Analysis Info

Analysis Name O43822SK.d
Method esi wide pos.m
Sample Name YL025
Comment

Acquisition Date 3/11/2019 2:55:46 PM
Operator admin
Instrument micrOTOF

Acquisition Parameter

Source Type	ESI	Capillary	4500 V	Nebulizer	0.3 Bar	Corona	196 nA
Ion Polarity	Positive	Set Capillary Exit	150.0 V	Dry Gas	4.0 l/min	Set Hexapole RF	300.0 V
n/a	n/a	Set Skimmer 1	50.0 V	Dry Heater	200 °C	APCI Heater	514 °C





Bruker Daltonics DataAnalysis 3.1

printed: 3/11/2019 3:02:34 PM

Page 1 of 1

Figure S79. Partial Mass Spectrum of 13






Figure S80. ^{31}P NMR spectra of crude complex **8** in the presence of excess ligand **1** (1.2 equiv) **(a)** and crude mixtures of complexes **11/12** respectively with a 1:1 **(b)** and a 1:2 **(c)** metal/ligand ratio.

5. Crystal structure analyses

Compound 8: Crystal suitable for X-ray crystal-structure analysis of **8** was obtained as described in the synthetic procedures. Data were collected at 173(2) K on a Bruker APEX-II Duo KappaCCD diffractometer (Mo-K α radiation, $\lambda = 0.71073$ Å). The structure was solved by direct methods (SHELXS-2013) and refined against F₂ using the SHELXL-2014 software.⁹ The non-hydrogen atoms were refined anisotropically, using weighted full-matrix least-squares on F₂. The H-atoms were included in calculated positions and treated as riding atoms using SHELXL default parameters. Residual electronic density is due to the presence of a butanone molecule, the contribution of which has been taken out by the SQUEEZE procedure in the final refinement.¹⁰ The compound crystallizes with another butanone molecule in the monoclinic *P*2₁ space group, which is chiral. The Flack parameter is -0.009(11). The crystallographic data are reported in table S1.

Compounds 9, 10, 11, 12, 13: Crystals suitable for X-ray crystal-structure analysis of **9, 10, 11, 12, 13** were obtained as described in the synthetic procedures. Data were collected at 120(2) K on a Bruker PHOTON-III CPAD (Mo-K α radiation, $\lambda = 0.71073$ Å or Cu-K α radiation, $\lambda = 1.54178$ Å). The structures were solved by direct methods (SHELXT-2014) and refined against F₂ using the SHELXL-2014 software.⁹ The non-hydrogen atoms were refined anisotropically, using weighted full-matrix least-squares on F₂. The H-atoms were included in calculated positions and treated as riding atoms using SHELXL default parameters. The crystallographic data are reported in table S2, S3, S4, S5, S6.

Compound 9: The Ni complex co-crystallizes with two molecules of benzene, (one of which is located inside the cavity) and with half a molecule of benzene disordered with half a molecule of pentane. One methyl group (C57) is disordered over two positions. The compound crystallizes in the tetragonal *P*4₁2₁2 space group, which is chiral. The Flack parameter is 0.016(2).

Compound 10: Although achiral, the Ni complex has crystallized in the triclinic *P*1 chiral space group hence a Flack parameter of 0.014(3). This is due to the presence of a pair of

Ni complexes in the asymmetric unit, which when taken together are chiral. Each unit cell contains only one of the two possible enantiomeric dimers.

Compound **11**: A pair of Pd complexes co-crystallizes with 4 CHCl₃ solvent molecules.

Compound **12**: A pair of cationic Pd complexes co-crystallizes with 4 water molecules which form a hydrogen bond network with the chloride counter-anions. This compound has crystallized in the non-centrosymmetric orthorhombic *Pna2₁* space group.

Compound **13**: The Au complex co-crystallizes with a benzene molecule located in the CD cavity. A SQUEEZE procedure has been used to eliminate residual density due to one and a half disordered additional benzene molecules.¹⁰ The compound crystallizes in the monoclinic *C2* space group, which is chiral. The Flack parameter is 0.171(4), which deviates from zero. This happens because the structure contains significant anomalous scatterers. The absolute configuration was established based on the known absolute configuration of the CD.

Table S1. Crystallographic and structure refinement data for **9** (CCDC 2163663)

Crystal Data	
Crystal size/mm ³	0.3 x 0.2 x 0.15
Empirical formula	2(C ₆₀ H ₁₀₀ NNiO ₂₈ PNiBr ₂)•5(C ₆ H ₆)•C ₅ H ₁₂
Formula Weight	3528.49
Crystal system	tetragonal
Space group	<i>P</i> 4 ₁ 2 ₁ 2
Temperature/K	120(2)
Unit cell parameters	
a/Å	17.8671(6)
b/Å	17.8671(6)
c/Å	53.805(2)
α /°	90
β /°	90
γ /°	90
V/Å ³	17176.2(14)
Z	4
D _(calc) g/cm ³	1.364
F (000)	7440.0
μ /mm ⁻¹	1.252

Data Processing and Reduction	
2θ range for data collection/ $^{\circ}$	3.79 to 55.792
Index ranges	$-23 \leq h \leq 23$, $-23 \leq k \leq 23$, $-70 \leq l \leq 68$
Reflections collected	277051
Independent reflections	20499 [$R_{\text{int}} = 0.0618$, $R_{\text{sigma}} = 0.0391$]
Data / restraints / parameters	20499/0/919
Goodness-of-fit on F^2	1.040
Final R indices [$I > 2\sigma(I)$]	$R_1 = 0.0515$, $wR_2 = 0.1343$
R indices (all data)	$R_1 = 0.0741$, $wR_2 = 0.1474$
Largest diff. peak and hole/ $\text{e}\text{\AA}^{-3}$	0.80/-0.81
Flack parameter	0.016(2)




Figure S81. Crystal structure of **9** with H atoms and solvent molecules omitted for clarity

Table S2. Crystallographic and structure refinement data for **10** (CCDC 2163657)

Crystal Data	
Crystal size/mm ³	0.18 x 0.15 x 0.12
Empirical formula	C ₁₂ H ₂₀ NPNiBr ₂
Formula Weight	427.79
Crystal system	triclinic
Space group	<i>P</i> 1
Temperature/K	120(2)
Unit cell parameters	
a/Å	7.2760(3)
b/Å	8.6431(3)
c/Å	13.5955(5)
α /°	83.1970(10)
β /°	84.0140(10)
γ /°	71.1770(10)
V/Å ³	801.57(5)
<i>Z</i>	2
D _(calc) g/cm ³	1.772
F (000)	424.0
μ /mm ⁻¹	6.275

Data Processing and Reduction	
2θ range for data collection/ $^{\circ}$	5 to 55.84
Index ranges	$-9 \leq h \leq 9$, $-11 \leq k \leq 11$, $-17 \leq l \leq 17$
Reflections collected	54711
Independent reflections	7331 [$R_{\text{int}} = 0.0369$, $R_{\text{sigma}} = 0.0276$]
Data / restraints / parameters	7331/3/315
Goodness-of-fit on F^2	1.077
Final R indices [$I > 2\sigma(I)$]	$R_1 = 0.0182$, $wR_2 = 0.0362$
R indices (all data)	$R_1 = 0.0203$, $wR_2 = 0.0376$
Largest diff. peak and hole/ $\text{e}\text{\AA}^{-3}$	0.54/-0.72
Flack parameter	0.014(3)




Figure S82. Crystal structure of **10** with H atoms and solvent molecules omitted for clarity

Table S3. Crystallographic and structure refinement data for **8** (CCDC 2163655)

Crystal Data	
Crystal size/mm ³	0.25 x 0.12 x 0.1
Empirical formula	C ₆₀ H ₁₀₀ NO ₂₈ PCl ₂ Pd•C ₄ H ₈ O
Formula Weight	1563.78
Crystal system	monoclinic
Space group	<i>P</i> 2 ₁
Temperature/K	173(2)
Unit cell parameters	
a/Å	14.9237(6)
b/Å	17.5343(7)
c/Å	15.7250(6)
α /°	90
β /°	101.0630(10)
γ /°	90
V/Å ³	4038.4(3)
Z	2
D _(calc) g/cm ³	1.286
F (000)	1652.0
μ /mm ⁻¹	0.391

Data Processing and Reduction	
2θ range for data collection/ $^{\circ}$	3.446 to 56.042
Index ranges	$-19 \leq h \leq 19$, $-20 \leq k \leq 23$, $-20 \leq l \leq 20$
Reflections collected	39896
Independent reflections	18579 [$R_{\text{int}} = 0.0509$, $R_{\text{sigma}} = 0.0849$]
Data / restraints / parameters	18579/2/897
Goodness-of-fit on F^2	0.955
Final R indices [$I > 2\sigma(I)$]	$R_1 = 0.0478$, $wR_2 = 0.0893$
R indices (all data)	$R_1 = 0.0810$, $wR_2 = 0.0978$
Largest diff. peak and hole/ $\text{e}\text{\AA}^{-3}$	0.53/-0.64
Flack parameter	0.002(11)




Figure S83. Crystal structure of **8** with H atoms and solvent molecules omitted for clarity

Table S4. Crystallographic and structure refinement data for **11** (CCDC 2163751)

Crystal Data	
Crystal size/mm ³	0.15 x 0.1 x 0.08
Empirical formula	C ₁₂ H ₂₀ NPPdCl ₂ •2(CHCl ₃)
Formula Weight	625.29
Crystal system	monoclinic
Space group	<i>P</i> 2 ₁ / <i>c</i>
Temperature/K	120(2)
Unit cell parameters	
a/Å	17.0385(7)
b/Å	8.8900(3)
c/Å	32.4365(14)
α/°	90
β/°	92.933(2)
γ/°	90
V/Å ³	4906.8(3)
Z	8
D _(calc) g/cm ³	1.693
F (000)	2480.0
μ/mm ⁻¹	1.694

Data Processing and Reduction	
2θ range for data collection/ $^{\circ}$	4.752 to 58.102
Index ranges	$-23 \leq h \leq 23$, $-12 \leq k \leq 11$, $-44 \leq l \leq 44$
Reflections collected	145578
Independent reflections	13078 [$R_{\text{int}} = 0.1059$, $R_{\text{sigma}} = 0.0475$]
Data / restraints / parameters	13078/0/459
Goodness-of-fit on F^2	1.060
Final R indices [$I > 2\sigma(I)$]	$R_1 = 0.0423$, $wR_2 = 0.0784$
R indices (all data)	$R_1 = 0.0712$, $wR_2 = 0.0920$
Largest diff. peak and hole/ $\text{e}\text{\AA}^{-3}$	1.28/-1.04




Figure S84. Crystal structure of **11** with H atoms and solvent molecules omitted for clarity

Table S5. Crystallographic and structure refinement data for **12** (CCDC 2163658)

Crystal Data	
Crystal size/mm ³	0.14 x 0.12 x 0.1
Empirical formula	C ₂₄ H ₄₀ N ₂ P ₂ PdCl ₂ •2(H ₂ O)
Formula Weight	631.85
Crystal system	orthorhombic
Space group	<i>Pna</i> 2 ₁
Temperature/K	120(2)
Unit cell parameters	
a/Å	13.1872(4)
b/Å	11.4097(3)
c/Å	38.4881(11)
α /°	90
β /°	90
γ /°	90
V/Å ³	5791.0(3)
Z	8
D _(calc) g/cm ³	1.449
F (000)	2624.0
μ /mm ⁻¹	0.959

Data Processing and Reduction	
2θ range for data collection/ $^{\circ}$	4.234 to 56.032
Index ranges	$-17 \leq h \leq 17$, $-15 \leq k \leq 15$, $-50 \leq l \leq 50$
Reflections collected	94671
Independent reflections	13931 [$R_{\text{int}} = 0.0609$, $R_{\text{sigma}} = 0.0429$]
Data / restraints / parameters	13931/1/611
Goodness-of-fit on F^2	1.069
Final R indices [$I > 2\sigma(I)$]	$R_1 = 0.0350$, $wR_2 = 0.0719$
R indices (all data)	$R_1 = 0.0464$, $wR_2 = 0.0783$
Largest diff. peak and hole/ $\text{e}\text{\AA}^{-3}$	2.45/-0.64




Figure S85 Crystal structure of **12** with H atoms and solvent molecules omitted for clarity

Table S6. Crystallographic and structure refinement data for **13** (CCDC 2163666)

Crystal Data	
Crystal size/mm ³	0.35 x 0.2 x 0.15
Empirical formula	C ₆₀ H ₁₀₀ NO ₂₈ PAuCl•C ₆ H ₆
Formula Weight	1624.90
Crystal system	monoclinic
Space group	<i>C</i> 2
Temperature/K	120(2)
Unit cell parameters	
a/Å	38.308(6)
b/Å	14.1787(6)
c/Å	15.4860(2)
α /°	90
β /°	93.007(2)
γ /°	90
V/Å ³	8399.7(8)
Z	4
D _(calc) g/cm ³	1.285
F (000)	3376.0
μ /mm ⁻¹	4.367

Data Processing and Reduction	
2θ range for data collection/°	4.62 to 134.642
Index ranges	$-45 \leq h \leq 45$, $-16 \leq k \leq 16$, $-18 \leq l \leq 18$
Reflections collected	108770
Independent reflections	14764 [$R_{\text{int}} = 0.0684$, $R_{\text{sigma}} = 0.0434$]
Data / restraints / parameters	14764/0/902
Goodness-of-fit on F^2	1.154
Final R indices [$I > 2\sigma(I)$]	$R_1 = 0.0409$, $wR_2 = 0.0969$
R indices (all data)	$R_1 = 0.0419$, $wR_2 = 0.0980$
Largest diff. peak and hole/ $\text{e}\text{\AA}^{-3}$	1.31/-0.81
Flack parameter	0.147(8)




Figure S86. Crystal structure of **13** with H atoms and solvent molecules omitted for clarity

6. UV-visible spectra




Figure S87. UV-vis spectra (CH₂Cl₂, 25°C) of cavity-shaped Ni complex **9** (black) and cavity-free Ni complex **10** (red). The UV-vis spectra feature a shoulder at 290-350 nm and two absorption maxima at 401, 536 nm for **9** and 384, 528 nm for **10**.




Figure S88. UV-vis spectra (CH₂Cl₂, 25°C) of cavity-shaped Pd complex **8** (black) and cavity-free complexes **11** (red) and **12** (green). The UV-vis spectra feature two absorption maxima at 293, 351 nm for **8** and 275, 345 nm for **11**. The spectrum of **12** shows a broad band between 300-330 nm.

References

1. D. Armspach, L. Poorters, D. Matt, B. Benmerad, F. Balegroune and L. Toupet, 1. D. Armspach, L. Poorters, D. Matt, B. Benmerad, F. Balegroune and L. Toupet, *Org. Biomol. Chem.*, 2005, **3**, 2588-2592.
2. A. Bessmertnykh, C. M. Douaihy, S. Muniappan and R. Guillard, *Synthesis*, 2008, 1575-1579.
3. H. Gilman and I. Banner, *J. Am. Chem. Soc.*, 1940, **62**, 344-345.
4. F. G. Mann and H. R. Watson, *J. Chem. Soc.*, 1957, 3945-3949.
5. F. Benvenuti, C. Carlini, M. Marchionna, R. Patrini, A. M. Raspolli Galletti and G. Sbrana, *J. Mol. Catal. A Chem.*, 1999, **140**, 139-155.
6. I. Bonnaventure and A. B. Charette, *J. Org. Chem.*, 2008, **73**, 6330-6340.
7. F. Y. Xu, O. M. Duke, D. Rojas, H. M. Eichelberger, R. S. Kim, T. B. Clark and D. A. Watson, *J. Am. Chem. Soc.*, 2020, **142**, 11988-11992.
8. P. H. M. Budzelaar, J. A. van Doorn and N. Meijboom, *Recl. Trav. Chim.*, 1991, **110**, 420-432.
9. G. M. Sheldrick, *Acta Crystallogr.*, 2008, **A64**, 112-122.
10. A. L. Spek, *Acta Crystallogr.*, 2009, **D65**, 148-155.